iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates
EMA granted clearance to advancebelrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in ...
Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Less frequent IV dosing with nemvaleukin in patients with select advanced solid tumors, including ovarian cancer and mucosal melanoma, showed ...
pharmaphorum2d
ESMO: GSK, iTeos bring some optimism back to TIGIT
The results of the GALAXIES Lung-02 study reported at the ESMO congress in Barcelona showed that the drug – added to GSK's PD-1 inhibitor Jemperli (dostarlimab) – achieved a higher objective ...
pharmaphorum1d
Jazz adds first immuno-oncology drug via $1.3bn Werewolf deal
Jazz Pharma has bolstered its pipeline of cancer drugs through a $1.3 billion licensing agreement with Werewolf Therapeutics that adds its first immuno-oncology candidate. The Dublin-based pharma ...
UroToday2d
European Society for Medical Oncology (ESMO) 2024 Annual Congress Coverage Starts Friday
At ESMO 2024, Bayer will present key results from the Phase III ARANOTE trial on NUBEQA® (darolutamide) for metastatic hormone-sensitive prostate cancer and the PEACE-III study of XOFIGO® (radium-223) ...
Indiatimes4d
Bharat Immunological & Biologicals Corporation Share Price
Bharat Immunological & Biologicals Corporation Ltd., incorporated in the year 1989, is a Small Cap company (having a market cap of Rs 109.89 Crore) operating in Pharmaceuticals sector. Bharat ...